MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers
| Autor: | Jiajia Gu, Guojing Zhang, Puyu Shi, Taofeek K. Owonikoko, Weilong Yao, Suresh S. Ramalingam, Shi-Yong Sun |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
MAPK/ERK pathway
Cancer Research biology medicine.diagnostic_test business.industry Cell Flow cytometry 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Oncology Apoptosis In vivo 030220 oncology & carcinogenesis Cancer research biology.protein Medicine Osimertinib 030212 general & internal medicine Epidermal growth factor receptor business EGFR inhibitors |
| Zdroj: | Cancer. 126:3788-3799 |
| ISSN: | 1097-0142 0008-543X |
| Popis: | Background The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. The current study focuses on determining whether targeting MEK/ERK signaling prevents or delays the development of acquired resistance to osimertinib. Methods Drug effects on cell survival were determined by measuring cell number alterations. Apoptosis was assessed with flow cytometry for the detection of annexin V-positive cells and with Western blotting for protein cleavage. Alterations of proteins in cells were detected with Western blotting. Drug effects on delaying the emergence of osimertinib resistance were evaluated with colony formation in vitro and xenografts in nude mice in vivo. Results Osimertinib combined with an MEK or ERK inhibitor synergistically decreased cell survival with enhanced induction of apoptosis in EGFR-mutant NSCLC cells but not in EGFR wild-type NSCLC cells. These combinations were also very effective in killing cell clones with primary intrinsic resistance to osimertinib. Continuous and intermittent pharmacologic inhibition of MEK/ERK signaling delayed the emergence of osimertinib resistance both in vitro and in vivo. Conclusions These results provide strong preclinical evidence in support of targeting MEK/ERK signaling as a strategy for delaying or preventing acquired resistance to osimertinib in the clinic to improve the long-term therapeutic efficacy of osimertinib. From a clinical standpoint, the data support the evaluation of an intermittent treatment schedule of osimertinib in combination with an MEK or ERK inhibitor in patients with EGFR-mutated NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text